Sybrava Injection 284 mg Solution for Injection
PDF Leaflet Revision Date: 29 October 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and statin therapy for primary hyperlipidaemia.
Dosage (summary)
284 mg subcutaneously initially, at 3 months, then every 6 months.
Onset of Action / Duration
Onset: 14 days, Duration: 6 months
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Atorvastatin
- Rosuvastatin
Contraindications
- Hypersensitivity to inclisiran or excipients
Common side effects
- Injection site reaction
- Injection site pain
- Injection site erythema
Counselling Points
- Administer in the abdomen
- Inspect for particulates before use
- Single use only
Serious warnings
- Use with caution in severe hepatic impairment
- Haemodialysis not for 72 hours post-dosing
Important Disclaimer
The Sybrava Injection 284 mg Solution for Injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
